Insulet Corporation (NASDAQ: PODD), a provider of tubeless insulin pump technology with its Omnipod brand of products, reported on Tuesday that its Omnipod 5 Automated Insulin Delivery System has received CE marking under the European Medical Device Regulation.
Omnipod 5 is designed for individuals aged two years and older with type 1 diabetes and is the first CE marked tubeless hybrid closed loop system (also known as automated insulin delivery) that integrates with the Dexcom G6 Continuous Glucose Monitoring (CGM) System to automatically adjust insulin and help protect against high and low glucose levels.
The company said its system consists of the tubeless Pod enhanced with SmartAdjust technology, the Omnipod 5 Controller with its integrated SmartBolus Calculator, and the Dexcom G6 CGM.
SmartAdjust technology receives a CGM value and trend very five minutes. It predicts where glucose will be 60 minutes into the future and then increases, decreases, or pauses insulin delivery based on the user's desired and customised glucose target.
Insulet added that it expects Omnipod 5 to be available in selected countries starting mid-2023.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes